Critical Control Point Model In PAT Guidance Supported By Industry
This article was originally published in The Tan Sheet
Executive Summary
FDA should adopt a critical control point model requiring firms only maintain data that pertain to significant manufacturing stages when drafting its Process Analytical Technology guidance, industry reps suggest
You may also be interested in...
PAT Guidance Will Draw From Existing Electronic Records Guidances
FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
FDA Risk-Based Part 11 Proposal Expected By February 2003
FDA intends to issue a policy statement on how its risk-based Good Manufacturing Practices initiative will affect 21 CFR Part 11 - the electronic records and electronic signatures reg - by early next year
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC